ArticleDrug safety2021
A Comparative View of Reported Adverse Effects of Statins in Social Media, Regulatory Data, Drug Information Databases and Systematic Reviews.
Article in Drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Comparative Analysis of Potential Side Effects of Targeted Oral Hypoglycemic Agents Using Spontaneous Adverse Event Reports and Social Media Data.Pharmacoepidemiology and drug safety · 2026Article
- Detecting Adverse Drug Events in Social Media: A Brief Literature Review.SN computer science · 2026Article
- The Value of Social Media Analysis for Adverse Events Detection and Pharmacovigilance: Scoping Review.JMIR public health and surveillance · 2024Article
- Social Media Posts on Statins: What Can We Learn About Patient Experiences and Perspectives?Journal of the American Heart Association · 2024Article
- Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study.Drug safety · 2023Article
- Patient safety discourse in a pandemic: a Twitter hashtag analysis study on #PatientSafety.Frontiers in public health · 2023Article
- Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study.JMIR formative research · 2022Article
- Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media.Drug safety · 2022Article
- Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers.Scientific reports · 2022Article
- Methods to Establish Race or Ethnicity of Twitter Users: Scoping Review.Journal of medical Internet research · 2022Article
- SEED: Symptom Extraction from English Social Media Posts using Deep Learning and Transfer Learning.medRxiv : the preprint server for health sciences · 2022Article
- Engaging PatientsFrontiers in pharmacology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
introductionThere are few studies assessing how data on adverse drug events from consumers on social media compare with other sources.
aimThe aim of this study was to assess the consistency of adverse event data of statin medications from social media as compared with other sources.
methodsWe collected data on the adverse events of statins from Twitter, the US FDA Adverse Event Reporting System (FAERS), the UK Medicines and Healthcare products Regulatory Agency (MHRA), drug information databases (DIDs) and systematic reviews. We manually annotated 12,649 tweets collected between June 2013 and August 2018. We collected 45,447 reports from FAERS, 10,415 from MHRA, identified 17 systematic reviews with relevant data and extracted data from Facts and Comparisons
resultsCompared with other sources, patients on social media are proportionally far more likely to complain about musculoskeletal symptoms than other adverse events. Most adverse events showed a high level of agreement between Twitter and regulatory data. DIDs tend to demonstrate similar patterns but not as strongly. Systematic reviews tend to examine pre-specified adverse events or those reported by trial investigators.
conclusionsCombining the data from multiple sources, albeit challenging, may provide a broader safety profile of any medication. Systematically collected social media reports may be able to contribute information on the most pertinent adverse effects to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.